According to Deutsche Bank, Merck & Co MRK announced this week that they had established a broad HCV alliance, across all major facets of the therapeutic area, including marketing, diagnostics, and R&D.
Deutsche Bank said that as part of the agreement, Roche will co-promote MRK's Victrelis in the US and the companies will work together to improve HCV awareness, diagnosis, and treatment in this market. “In addition, they intend to extend their alliance to other developed and emerging markets.”
Merck & Co closed yesterday at $37.27.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in